| Date | Title | Description |
| 18.03.2026 | Breakout Ventures: $114 Million Fund III Launched To Back Frontier Science Startups | Breakout Ventures has announced the close of its $114 million Fund III, marking a new phase of investment focused on science-driven startups at the intersection of biology, chemistry, and artificial intelligence.
The San Francisco-based ven... |
| 10.03.2026 | Breakout Ventures: $114 Million Fund III Launched To Back Science-Driven Startups Using AI | Breakout Ventures announced the close of its $114 million Fund III, expanding the venture firm’s efforts to back early-stage companies working at the intersection of science, technology, and artificial intelligence. The San Francisco-based ... |
| 05.02.2026 | Startups make leadership changes amid growth |
Loft Dynamics, the pioneer behind the world’s first EASA- and FAA-qualified virtual reality (VR) flight simulators, has appointed Sebastien Borel as chief executive officer, succeeding Founder Fabi Riesen who will serve as chief technology... |
| 27.12.2024 | FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo | FDA approves injectable version of Bristol Myers Squibb's cancer drug Opdivo
By Sneha S K and Sriparna RoyDecember 27, 20245:16 PM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
Bottles and a IV b... |
| 25.04.2022 | Halozyme Buys Antares for $960M | In a deal showcasing Halozyme Therapeutics as an ongoing leader in drug delivery, the San Diego-based biotech announced earlier this month (April 13) it had entered into a definitive agreement to acquire New Jersey-based Antares Pharma for ... |
| 13.04.2022 | Antares Pharma Stock Soars After $960 Million Halozyme Buyout | Shares of Antares Pharma surged 49% Wednesday after the specialty pharmaceutical company agreed to be bought by Halozyme Therapeutics in a cash deal valued at $960 million.
Under terms of the deal, Halozyme (ticker: HALO) will pay $5.60 a s... |
| 03.02.2022 | Halozyme Appoints New Chief Financial Officer | SAN DIEGO, Feb. 2, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Nicole LaBrosse has been promoted to the position of senior vice president, chief financial officer, effective immediately. Ms. LaBrosse... |
| 10.01.2022 | HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK | SAN DIEGO, Jan. 10, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today introduced 2022 financial guidance and commented on its outlook for the upcoming year.
"Halozyme had another strong year of financial performance... |
| 14.12.2021 | HALOZYME APPOINTS NEW GENERAL COUNSEL | SAN DIEGO, Dec. 13, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Mark Snyder has been appointed senior vice president, general counsel, chief compliance officer and corporate secretary, effective Janu... |
| 10.12.2021 | Halozyme Therapeutics, Inc. announces an Equity Buyback for $750 million worth of its shares. | Halozyme Therapeutics, Inc. (NasdaqGS:HALO) announces a share repurchase program. Under the program, the company will repurchase up to $750 million worth of its outstanding common stock. The Company plans to fund repurchases from its existi... |
| 10.12.2021 | HALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE REPURCHASE PROGRAM | SAN DIEGO, Dec. 9, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that its Board of Directors has approved a new share repurchase program effective immediately, which authorizes the Company to purchase up to... |
| 01.12.2021 | Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma Afte... | SAN DIEGO, Dec. 1, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-... |
| 02.11.2021 | Halozyme Reports Third Quarter 2021 Results | SAN DIEGO, Nov. 2, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2021 and provided an update on its recent corporate activities and outlook.
"... |
| 09.08.2021 | Halozyme Therapeutics : Reports Second Quarter 2021 Results | SAN DIEGO, Aug. 9, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the second quarter ended June 30, 2021 and provided an update on its recent corporate activities and outlook.
"Our ... |
| 09.08.2021 | Halozyme Reports Second Quarter 2021 Results | |
| 09.08.2021 | Halozyme Therapeutics : Inspire Week – Highlighting the Importance of Recharging the Mind, Body and Spirit | By Halozyme
August 9, 2021
Thank you to our patients, partners and shareholders for your continued support as we've learned to navigate through these unprecedented times together. We have all worked through many challenges during this pande... |
| 12.07.2021 | Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Aft... | |
| 12.07.2021 | Halozyme Therapeutics : Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Pomalidomide and Dexamethasone for Patients with Multi... | SAN DIEGO, July 12, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that Janssen Biotech, Inc. (Janssen) received U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluron... |
| 22.06.2021 | Halozyme Therapeutics : Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-T... | SAN DIEGO, June 22, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the European Commission (EC) has granted the Janssen Pharmaceutical Companies of Johnson & Johnson two marketing authorizations for... |
| 22.06.2021 | Halozyme Announces Janssen Receives European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-chain Amyloidosis and Pre-Treated Multiple... | |
| 21.05.2021 | Halozyme Announces Janssen Receives Two Positive CHMP Opinions for DARZALEX® (daratumumab) Subcutaneous Formulation Utilizing ENHANZE® | |
| 24.02.2021 | Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027 | |
| 23.02.2021 | Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027 | |
| 23.02.2021 | Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results | SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on its recent corporate activities and ... |
| 23.02.2021 | Halozyme Reports Fourth Quarter 2020 Results And Full Year 2020 Results | |
| 15.01.2021 | Halozyme Announces Janssen Receives FDA Approval Of DARZALEX FASPRO® (Daratumumab And Hyaluronidase-fihj) As Treatment For Newly Diagnosed Patients With Light Chain (AL) Amyloidosis | |
| 23.12.2020 | Halozyme Announces Roche Receives European Commission Approval For Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For T... | |
| 23.11.2020 | Horizon Therapeutics plc and Halozyme Therapeutics, Inc. Enter Global Collaboration and License Agreement for ENHANZE® Technology | |
| 23.11.2020 | Halozyme Raises Full Year 2020 Guidance | |
| 13.11.2020 | Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo® (Fixed-Dose Combination Of Perjeta® And Herceptin® For Subcutaneous Injection) Utilizing Halozyme's ENHANZE® Technology For HER2-Posit... | |
| 12.11.2020 | Halozyme Announces Janssen Submission Of Applications In US And EU Seeking Approval Of DARZALEX FASPRO™/ DARZALEX® Subcutaneous (SC) Formulation Utilizing ENHANZE® Technology, Combination With Pomalid... | |
| 05.11.2020 | Halozyme Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting For APOLLO and ANDROMEDA Phase 3 Studies By Janssen Evaluating Subcutaneous Daratumumab Utilizing ENHANZ... | |
| 02.11.2020 | Halozyme Reports Third Quarter 2020 Results And Raises Full Year 2020 Guidance | |
| 05.11.2019 | Halozyme to restructure after failure of pivotal pancreatic cancer study | “Based on the preclinical and Phase II data, we believed a targeted approach with a differentiated mechanism of action had a strong chance to make a breakthrough in this incredibly challenging cancer,” Halozyme CEO Helen Torley said Monday ... |
| 04.02.2019 | Halozyme scores $30M in cash for its latest alliance; Bernie Sanders takes aim at $375,000 rare disease drug | → Now it’s argenx’s turn to sign up on a collaboration deal with Halozyme aimed at using their platform tech to create subcutaneous versions of their therapies. Halozyme is getting $30 million upfront for 3 programs, with ... |
| 31.03.2017 | Halozyme slides on an early futility failure for its lead cancer therapy | Helen Torley
Halozyme shares slipped 8% on Thursday after the biotech reported that one of its combo studies using PEGPH20 couldn’t clear an early test for futility.
Investigators were using a combination of PEGPH20 plu... |
| 11.11.2016 | Bristol-Myers partners with Johns Hopkins on Opdivo pact; A Valeant by any other name… | Johns Hopkins scientists will go to work studying Bristol-Myers Squibb’s Opdivo and Yervoy, looking for their weak points as the company looks to improve on these blockbuster drugs. They’ll be studying patient tumor sample... |
| 25.07.2016 | Protocols: Tricida bags $55M round for CKD drug; $MRK gets a 'breakthrough’; | South San Francisco-based Tricida has brought its total fundraising to $95 million, with a new $55 million C round earmarked to fund its work on an experimental therapy for chronic kidney disease. Company CEO Gerrit Kla... |
| 27.01.2016 |
Halozyme Raises $150M In Debt Funding
| San Diego-based biopharmaceuticals developer Halozyme Therapeutics said yesterday that it has raised $150M in royalty-backed, debt financing. The financing came from Pharmakon Advisors and Athyrium Capital Management. According to the compa... |
| 05.01.2016 |
Halozyme Finds $150M In Debt Financing For Cancer Efforts
| San Diego-based Halozyme Therapeutics, the publicly held cancer therapeutics developer, has entered into a $150M credit agreement, the company said this morning. The debt funding comes from Pharmakon Advisors and Athyrium Capital Management... |
| 24.10.2014 | Organovo CEO: Closing IPO Window Could Spur More Reverse Mergers | Share Share on Facebook Share on Twitter LinkedIn Email Reprints
Shifting perceptions and a cooling IPO market could lead more biotech startups to join a public stock exchange via a reverse merger with a shell company that is already public... |
| 03.02.2014 | Halozyme Announces $100M Common Stock Offering | San Diego cancer drug company Halozyme Therapeutics Inc. has announced a $100 million public offering of its stock.
Shares for Halozyme (Nasdaq: HALO) dropped more than 5 percent to $13.96 in after-hours trading following the news. The comp... |
| 06.01.2014 | Halozyme Secures Additional $20M Term Loan | Halozyme Therapeutics Inc. announced it has received an additional $20 million loan from Oxford Finance LLC and Silicon Valley Bank.
San Diego-based Halozyme extended its original $30 million amount by the additional $20 million term loan, ... |
| - | Halozyme Therapeutics, Inc. Announces Proposed Offering of $500 Million of Convertible Senior Notes due 2027 | SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced that it intends to offer, s... |
| - | Halozyme Therapeutics, Inc. Announces Pricing of Private Offering of $700 Million of Convertible Senior Notes due 2027 | SAN DIEGO, Feb. 24, 2021 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company"), a leader in converting IV biologics to subcutaneous delivery, today announced the pricing of $700 million... |
| - | Halozyme to restructure after failure of pivotal pancreatic cancer study | Biotech company Halozyme Therapeutics is laying off more than half its staff and pivoting its focus following the failure of its lead Phase III trial program.
The San Diego-based company said Monday that the Phase III HALO-301 trial of the ... |